Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Trends Endocrinol Metab. 2019 May 21;30(6):369–383. doi: 10.1016/j.tem.2019.04.004

Figure 1. Proposed Steps of Delivering Nano-encapsulated Anti-miR-33 Targeting Liver.

Figure 1.

Nano encapsulated anti-miR-33 rescues the fatty liver when delivered to the body. Increased miR-33 inhibits expression of genes in the liver which would otherwise stimulate insulin signaling, FA oxidation, HDL biogenesis, and bile secretion. Anti-miR-33 reverses the adverse metabolic effect and rescues the fatty liver and its downstream effect. Due to the liver specific coating, a significant portion would go to the liver and very little to other organs. FA-fatty acid. HDL-high density lipoprotein. WAT-white adipose tissue.